SAB Biotherapeutics Warrant
SABSW
10 hedge funds and large institutions have $88.4K invested in SAB Biotherapeutics Warrant in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 6 closing their positions.
2.35% less ownership
Funds ownership: 4.03% → 1.68% (-2.4%)
29% less funds holding
Funds holding: 14 → 10 (-4)
67% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 6
69% less capital invested
Capital invested by funds: $289K → $88.4K (-$201K)
86% less call options, than puts
Call options by funds: $7K | Put options by funds: $49K
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Clear Street
New York
|
+$10 |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$10 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Shaolin Capital Management
Miami,
Florida
|
-$52.1K |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$15.8K |
| 3 |
EPM
Equitec Proprietary Markets
Chicago,
Illinois
|
-$1.62K |
| 4 |
MC
Meteora Capital
Boca Raton,
Florida
|
-$1.28K |
| 5 |
FTUS
Flow Traders U.S.
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
LP
1
LMR Partners
London,
United Kingdom
| $56.3K | – | – | – |
|
2
Morgan Stanley
New York
| $15.5K | – | – | – |
|
|
YCM
3
Yakira Capital Management
Westport,
Connecticut
| $11.3K | – | – | – |
|
4
Walleye Capital
New York
| $2.43K | – | – | – |
|
5
Walleye Trading
New York
| $1.62K | – | – | – |
|
|
WAM
6
Wolverine Asset Management
Chicago,
Illinois
| $977 | -$358 | -3,425 | -27% |
|
|
NA
7
NewEdge Advisors
New Orleans,
Louisiana
| $112 | – | – | – |
|
|
CS
8
Clear Street
New York
| $10 | +$10 | +100 | New |
|
|
9
UBS Group
Zurich,
Switzerland
| $10 | +$10 | +100 | New |
|
|
TRCT
10
Tower Research Capital (TRC)
New York
| $5 | – | – | – |
|
|
SCM
11
Shaolin Capital Management
Miami,
Florida
| – | -$52.1K | -498,109 | Closed |
|
|
12
Balyasny Asset Management
Chicago,
Illinois
| – | -$15.8K | -281,107 | Closed |
|
|
EPM
13
Equitec Proprietary Markets
Chicago,
Illinois
| – | -$1.62K | -45,000 | Closed |
|
|
MC
14
Meteora Capital
Boca Raton,
Florida
| – | -$1.28K | -35,446 | Closed |
|
|
FTUS
15
Flow Traders U.S.
New York
| – | -$1K | -15,938 | Closed |
|
16
Jane Street
New York
| – | -$600 | -10,628 | Closed |
|
SABSW Hedge Fund Activity: Q2 2023 in Review
10 of the 6,371 institutional investors tracked by Wall St. Rank reported a position in SAB Biotherapeutics Warrant (SABSW) for Q2 2023, worth a combined $88.4K — down 69% from $289K a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of SABSW and 2 opened new positions — a net loss of 4 holders — while 1 trimmed existing stakes and 0 added.
The largest buyer was Clear Street, opening a new position worth an estimated $10. The largest seller was Shaolin Capital Management, exiting entirely with an estimated $52.1K sold.
- 10 institutional investors held SAB Biotherapeutics Warrant (SABSW) as of Q2 2023, down from 14 in Q1 2023.
- Funds reported $88.4K of SAB Biotherapeutics Warrant stock for Q2 2023, down 69% quarter-over-quarter.
- 2 funds opened new SAB Biotherapeutics Warrant positions in Q2 2023 and 6 closed out, a net change of -4 holders.
- The largest SAB Biotherapeutics Warrant buyer in Q2 2023 was Clear Street, an estimated $10 added.
- The largest SAB Biotherapeutics Warrant seller in Q2 2023 was Shaolin Capital Management, an estimated $52.1K sold.
Based on aggregated 13F filings for Q2 2023.